Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. May 28, 2014; 20(20): 6170-6179
Published online May 28, 2014. doi: 10.3748/wjg.v20.i20.6170
Published online May 28, 2014. doi: 10.3748/wjg.v20.i20.6170
Donor transmitted and de novo cancer after liver transplantation
Rajeev Desai, James Neuberger, NHS Blood and Transplant, Bristol B34 8RR, United Kingdom
Author contributions: Desai R performed the literature search, obtained the references and wrote the initial manuscript; Neuberger J contributed to the literature search, wrote and edited the manuscript.
Correspondence to: James Neuberger, Associate Medical Director, NHS Blood and Transplant, Fox Den Road, Bristol B34 8RR, United Kingdom. j.m.neuberger@bham.ac.uk
Telephone: +44-117-9757488 Fax: +44-117-9757577
Received: November 2, 2013
Revised: December 2, 2013
Accepted: January 3, 2014
Published online: May 28, 2014
Processing time: 206 Days and 16.7 Hours
Revised: December 2, 2013
Accepted: January 3, 2014
Published online: May 28, 2014
Processing time: 206 Days and 16.7 Hours
Core Tip
Core tip: Cancer is an important cause of morbidity and mortality after organ transplantation. Donor transmitted cancers are rare but when they occur, they can have significant impact on the recipient outcome. Screening of donors can reduce the risk of transmission of cancer but cannot eliminate it. So this risk should be accepted by the transplant teams and the recipients. The risk of many de novo cancers is increased among transplant recipients. Selection of immunosuppressive agents, minimizing the intensity of immunosuppression and modification of life-style related risk factors would contribute to reduction of the risk of post-transplant cancer.